https://www.selleckchem.com/products/repsox.html
3%; P= .066), 4 mg BID (46.3%; P= .059), and 4 mg QD (43.9%; P= .095) groups vs placebo (26.8%). Week 8 rates of clinical remission were 22.0% (P= .02, 24.4% (P= .013), and 24.4% (P= .011) in the 3 ivarmacitinib treatment groups, respectively, vs 4.9% for placebo. During the initial 8-week period, treatment-emergent adverse events occurred in 43.9% to 48.8% of ivarmacitinib-treated patients and in 39.0% of the placebo group, and were predominantly mild. There were no deaths, or major adverse cardiovascular or thromboembolic events. Iva
Like
Comment
Share
